Targeting Solid Tumors with pH-Dependent TCE: First in Human Development of CT-202

Publications

Apr 20

Written By Martin Lehr

Nectin

Martin Lehr

A Phase 1, First-in-Human Study of CT-95, a Mesothelin-Directed Bispecific T Cell Engager (TCE) in Subjects with Advanced Solid Tumors